Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Click here to view

Presentation

Process and Platform Development for Production and Purification of CNS-Tropic Engineered AAV Capsids

Download PDF